Cryptotanshinone attenuated pathological cardiac remodeling in vivo and in vitro experiments

HIGHLIGHTS

• who: Wen-jing Li et al. from the Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China have published the research: Cryptotanshinone Attenuated Pathological Cardiac Remodeling In Vivo and In Vitro Experiments, in the Journal: Oxidative Medicine and Cellular Longevity of 27/01/2023
• what: This study was aimed at assessing whether Cryptotanshinone (CTS) treatment could effectively attenuate cardiac remodeling in vivo and in vitro. This study showed that CTS administration has nonsignificant effect on MAPKs (p38, ERK1/2, and JNK1/2) and PI3K/AKT signaling pathways (Supplementary figure 1, D-F). This study . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.